Genzyme's Cancer Drug IP Suit Can Proceed, Judge Says

Law360, New York (February 6, 2014, 5:39 PM EST) -- Generic-drug maker Abon Pharmaceuticals LLC couldn't convince a New Jersey federal judge to toss Genzyme Corp. and the Southern Research Institute's patent suit over a leukemia treatment, with the court on Tuesday ruling that the plaintiffs have standing and Sanofi-Aventis U.S. LLC can also join the fray.  

In a 15-page opinion, U.S. District Court Judge Joseph E. Irenas granted Genzyme leave to file an amended complaint adding Sanofi, its parent company, to the suit against Abon, which it targeted over its interest in a generic...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.